Pharmafile Logo
Pharmafocus logo
Advanced Search

Doctors receiving drugmaker payments more likely to prescribe their products, BMJ study finds

August 22, 2016
Research and Development, Sales and Marketing

US physicians who received gifts and other payments from drug companies were more likely to prescribe branded anticoagulants and diabetes …

News
lab

MHRA suspends GMP certificate for Pfizer site in India

August 22, 2016
Manufacturing and Production, Sales and Marketing GMP, India, MHRA, Pfizer, ban, facility, import, suspend

The UK’s Medicines and Healthcare Products Agency (MHRA) has recommended that an Indian facility belonging to Pfizer’s Hospira unit be …

News
sanofi_multaq

FDA delays appraisal of Sanofi, Zealand diabetes drug just days before decision due

August 22, 2016
Research and Development, Sales and Marketing NDA, Sanofi, appraisal, diabetes, iglarlixi, type 2, type-2, zealand

There was unfortunate news for Sanofi and Zealand Pharma as the FDA announced that it required additional information, constituting a …

News

Pfizer acquires Medivation for $14 billion

August 22, 2016
Sales and Marketing Medivation, Pfizer, acquisition, oncology

Pfizer has sealed the deal to acquire US cancer drug company Medivation for close to $14 billion in a move …

News

FDA approves Pfizer’s abuse-deterrent opioid painkiller

August 22, 2016
Sales and Marketing FDA, Pfizer, abuse deterrent, abuse-deterrent, approval, opioid, troxyca

Pfizer has announced that the US FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for the …

News
4420456374_64a3d7e6aa

Top ten stories in the pharmaceutical industry this week

August 19, 2016
Medical Communications pharmafile, top ten

The end of another week, and from huge expansions and investments to some shocking and saddening tragedies, it’s been a …

News
teva_copy

EU grants marketing authorisation for Teva’s asthma drug Cinqaero

August 19, 2016
Medical Communications, Sales and Marketing EU, Teva, approval, asthma, cinqaero, eosinophilic

The European Commission has granted marketing authorisation for Teva’s Cinqaero (reslizumab), as an odd-on therapy in adult patients with severe …

News

Bayer’s liver cancer drug not cost-effective, says NICE

August 19, 2016
Medical Communications, Sales and Marketing Bayer, CDF, NICE, Nexavar, lung cancer

NICE has deemed Bayer’s liver cancer drug Nexavar (sorafenib) as not cost-effective. The drug is currently available on the Cancer …

News
gavel

Former shareholders sue Valeant, alleging “vast fraud”

August 19, 2016
Medical Communications, Sales and Marketing Valeant, fraud, lawsuit, t rowe price

Valeant Pharmaceuticals has confirmed that it is being sued by one its former largest shareholders, T Rowe Price, who claim …

News
clinical_trial_3

Intercept’s Ocaliva meets primary endpoint in Phase III trial for rare liver disease

August 18, 2016
Medical Communications, Research and Development intercept, ocaliva

Intercept Pharmaceuticals have announced the publication of Phase III results published in the New England Journal of Medicine, where Ocaliva …

News
shutterstock_512649

Chinese investors plan $1 billion US biotech site

August 18, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

China’s state-backed developer Greenland Holdings is set to jointly invested over $1 billion in a San Francisco-based biotech industrial park …

News
remicade_packshot

J&J loses Remicade patent fight, pledges to continue fight against biosimilars

August 18, 2016
Research and Development, Sales and Marketing Johnson and Johnson, Remicade, biosimilar, biosimilars, infliximab, patent

Johnson and Johnson has announced that it has lost in a patent dispute between biosimilar makers Celltrion and Hospira, relating …

News

Pfizer’s Xalkori price drop secures NICE recommendation

August 18, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Pfizer, Xalkori, crizotinib, lung cancer

The National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Xalkori (crizotinib) as a treatment for lung cancer, …

News
merck_incweb

MSD joins Medivation race, says reports

August 18, 2016
Manufacturing and Production, Research and Development, Sales and Marketing MSD, Medivation, Merck, Pfizer, Sanofi, Xtandi, takeover

MSD, known as Merck in the US and Canada, is said to have declared its interest in buying US oncology …

News

NICE says Afinitor and Imbruvica “may be removed” from Cancer Drugs Fund

August 18, 2016
Research and Development, Sales and Marketing Afinitor, Cancer Drugs Fund, Janssen, NICE, Novartis, imbruvica

NICE has published draft guidance advising the removal of Novartis’s Afinitor (everolimus) and Janssen’s Imbruvica (ibrutinib) from the Cancer Drugs …

News
chemo-web

Untested cancer drug suspected cause of three deaths at German alternative medicine centre

August 17, 2016
Research and Development 3-Bromopyruvate, Cancer, Germany, alternative medicine, patient deaths

The deaths of three patients at an alternative medicine clinic in Germany have prompted suspicion of a clinically untested cancer …

News
shutterstock_141299494

GSK, Roche and Novo back $86 million immuno-oncology startup

August 17, 2016
Research and Development CD47, Cancer, GSK, Novo, Roche, Tioma, oncology

Brisbane-based venture-stage biopharmaceutical company Tioma Therapeutics has announced it has raised $86 million in Series A venture financing for its …

News
praluent_75mg_pen_box_hr

Amgen, Sanofi cholesterol medicines “not cost-effective”, need to drop price by two-thirds

August 17, 2016
Research and Development, Sales and Marketing Amgen, QALY, Regeneron, Repatha, Sanofi, cost effective, cost-effective, praluent

A new study published in JAMA has suggested that Amgen, Sanofi and Regeneron would have to reduce their prices for …

News
landing-hero-images1

ViiV Healthcare launches Phase III trial for combo HIV treatment

August 16, 2016
Research and Development Dolutegravir, HIV, Tivicay, ViiV Healthcare, epivir, lamivudine, phase III

The Pfizer/GSK spin off ViiV Healthcare has announced the beginning of a Phase III evaluating Tivicay (dolutegravir) and Epivir (lamivudine) …

News
msd

MSD to cut 148 jobs at Pennsylvania plant

August 16, 2016
Manufacturing and Production, Research and Development MSD, job cuts, zontivity

MSD is due to cut 148 jobs at its North Wales, Pennsylvania campus effective September 12, according to the company’s …

News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026